The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases.

[1]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[2]  A. Bowcock,et al.  CARD14 Expression in Dermal Endothelial Cells in Psoriasis , 2014, PloS one.

[3]  J. Fechner,et al.  The Aryl Hydrocarbon Receptor Meets Immunology: Friend or Foe? A Little of Both , 2014, Front. Immunol..

[4]  M. Colonna.  AHR: making the keratinocytes thick skinned. , 2014, Immunity.

[5]  Frank O. Nestle,et al.  Activation of the Aryl Hydrocarbon Receptor Dampens the Severity of Inflammatory Skin Conditions , 2014, Immunity.

[6]  L. Arends,et al.  The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. , 2014, The Journal of investigative dermatology.

[7]  U. V. von Andrian,et al.  Nociceptive Sensory Neurons Drive Interleukin-23 Mediated Psoriasiform Skin Inflammation , 2014, Nature.

[8]  M. Suárez-Fariñas,et al.  Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights , 2014, The Journal of investigative dermatology.

[9]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.

[10]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[11]  J. Toldi,et al.  Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.

[12]  Suyan Tian,et al.  Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease , 2012, PloS one.

[13]  J. Harden,et al.  Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity , 2012, Immunological investigations.

[14]  Hideki Fujita,et al.  Combined Use of Laser Capture Microdissection and cDNA Microarray Analysis Identifies Locally Expressed Disease-Related Genes in Focal Regions of Psoriasis Vulgaris Skin Lesions , 2012, The Journal of investigative dermatology.

[15]  M. Weichenthal,et al.  Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis , 2012, Allergy.

[16]  C. Garlanda,et al.  AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch , 2011, Nature Immunology.

[17]  Alan Menter,et al.  A subset of methylated CpG sites differentiate psoriatic from normal skin , 2011, The Journal of investigative dermatology.

[18]  M. Suárez-Fariñas,et al.  Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity , 2011, The Journal of investigative dermatology.

[19]  M. Weller,et al.  An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor , 2011, Nature.

[20]  G. Lundkvist,et al.  Effects of pro-inflammatory cytokines on expression of kynurenine pathway enzymes in human dermal fibroblasts , 2011, Journal of Inflammation.

[21]  Lauren P. Virtuoso,et al.  Dichotomous Effects of IFN-γ on Dendritic Cell Function Determine the Extent of IL-12–Driven Antitumor T Cell Immunity , 2011, The Journal of Immunology.

[22]  T. Yeo,et al.  An Observational Cohort Study of the Kynurenine to Tryptophan Ratio in Sepsis: Association with Impaired Immune and Microvascular Function , 2011, PloS one.

[23]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[24]  M. Suárez-Fariñas,et al.  Resolved psoriasis lesions retain expression of a subset of disease-related genes. , 2011, The Journal of investigative dermatology.

[25]  M. Suárez-Fariñas,et al.  Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. , 2010, The Journal of investigative dermatology.

[26]  Lisa C. Zaba,et al.  A subpopulation of CD163-positive macrophages is classically activated in psoriasis. , 2010, The Journal of investigative dermatology.

[27]  J. Fechner,et al.  An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.

[28]  Luis Puig,et al.  Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.

[29]  Andrew Johnston,et al.  Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. , 2010, The Journal of investigative dermatology.

[30]  J. Stasch,et al.  Corrigendum: Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.

[31]  Mayte Suárez-Fariñas,et al.  Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA) , 2010, PloS one.

[32]  J. Stasch,et al.  Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.

[33]  N. Egilmez,et al.  Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. , 2010, Cancer research.

[34]  V. Meininger,et al.  The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis , 2010, Neurotoxicity Research.

[35]  Xing Li,et al.  Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. , 2009, The Journal of investigative dermatology.

[36]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[37]  C. MacKenzie,et al.  Antimicrobial and immunoregulatory effector mechanisms in human endothelial cells , 2009, Thrombosis and Haemostasis.

[38]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[39]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[40]  I. Bechmann,et al.  IDO expression in the brain: a double-edged sword , 2007, Journal of Molecular Medicine.

[41]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[42]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[43]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  K. Mitsuishi,et al.  Gene expression of enzymes for tryptophan degradation pathway is upregulated in the skin lesions of patients with atopic dermatitis or psoriasis. , 2004, Journal of dermatological science.

[45]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[46]  D. Munn,et al.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.

[47]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[48]  R. Carruthers.  LOW TRYPTOPHAN DIET IN TREATMENT OF PSORIASIS , 1968, The Medical journal of Australia.

[49]  R. Carruthers.  LOW TRYPTOPHAN DIET IN THE TREATMENT OF PSORIASIS , 1968 .

[50]  A. M. Lefkovits,et al.  Remission of psoriasis with low dietary tryptophan. , 1967, Lancet.